BioPharma « Terug naar discussie overzicht

Biophytis, de nieuwe raket?

64 Posts, Pagina: « 1 2 3 4 » | Laatste

Omlaag ↓

vantodim1970 30 oktober 2020 13:39

Weinig belangstelling hier, vandaag in ieder geval aan een mooie klim bezig. Zitten nu in fase 2/3 van hun geneesmiddel tegen de negatieve effecten van covid. Het is eens wat anders dan testers.

vantodim1970 2 november 2020 11:01

Vandaag opnieuw mooi groen, blijf nog even zitten.

Forecast2006 2 november 2020 22:04

Raar slot vandaag.

Biophytis bij De Giro plotsklaps van 0,71 naar 0,667 in de naveiling.

Morgen weer flink up.

Kind regards,

Forecast

Forecast2006 3 november 2020 06:39

Fout in de weergave van de koers gelukkig.

Vandaag richtng 0,80 cent moet lukken.

Kind regards,

Forecast

[verwijderd] 3 november 2020 14:29

quote:
Forecast2006 schreef op 3 november 2020 06:39:
Fout in de weergave van de koers gelukkig.

Vandaag richtng 0,80 cent moet lukken.

Kind regards,

Forecast

Terug naar 60 cent zit dichter in de buurt.

Forecast2006 4 november 2020 07:53

Covid-19 Test fase2/3 gestart op 26 oktober ( duur 28 dagen ) uitslag verwacht eind november.

Kind regards,

Forecast

vantodim1970 4 november 2020 09:24

zo hebben we weer iets om naar uit te kijken :-)

[verwijderd] 4 november 2020 09:36

Ik zit met een GAK van 0,75
Twijfel om rond de 0,6 in te kopen om het wat te verlagen
Wat is er nog meer de verwachting naast de gestarte testfase 2/3? Is er meer nieuws?

vantodim1970 5 november 2020 17:26

precies ineens wat koopdruk, zou er nieuws zijn? Ik kan in ieder geval niks vinden...

vantodim1970 5 november 2020 17:28

we krijgen zelfs nog en freeze voor het afsluiten vandaag, merkwaardig

[verwijderd] 5 november 2020 17:31

Heel apart dit, schiet omhoog...

Small_first-Steps 6 november 2020 09:52

Ben vorige week ingestapt in dit aandeel. Na een flinke lift en daarna een daling (GAK 0,72) hebben we gisteren wel een hele vreemde stijging gezien op het einde van de dag...
Blijf voorlopig rustig zitten en hopen op mooi nieuws om het aandeel verder omhoog te stuwen

[verwijderd] 13 november 2020 09:13

Weer 11% eraf. Is er nieuws?

vantodim1970 30 november 2020 10:04

[quote alias=Forecast2006 id=12875422 date=202011040753]
Covid-19 Test fase2/3 gestart op 26 oktober ( duur 28 dagen ) uitslag verwacht eind november.

Nog niks kunnen terug vinden op hun site, we stijgen echter wel vandaag...

vantodim1970 30 november 2020 14:45

correctie: we stegen

vantodim1970 9 december 2020 12:08

Ze gaan als een speer vandaag, eigenaardig ik vind nog steeds geen nieuws op hun site?

[verwijderd] 9 december 2020 15:28

Heb alles eruit gemieterd op 71.8
GAK was 75, maar zag dit als een eenmalige kans om het met een redelijk klein verlies te verkopen..
Blijft een waardeloos aandeel, geen nieuws, niks.
Zal straks wel weer terugvallen naar 60 oid
Mij niet meer gezien

vantodim1970 11 december 2020 10:36

Je had precies toch nog beter enkele dagen gewacht met verkopen...

vantodim1970 11 december 2020 10:42

Deze keer wel een stijging op nieuws, dit staat op de website:

Biophytis - First Patient Enrolled in France in COVA, an
International Phase 2/3 Clinical Trial with Sarconeos (BIO101)
for the Treatment of COVID-19 Related Respiratory Failure

First Patient Dosed at La Pitié-Salpêtrière University Hospital in Paris

Total of eight centers authorized by French National Health Agency
(ANSM) for patient recruitment in France

Paris, (France), Cambridge (Massachusetts, United States), December 11, 2020, 8:00 a.m. CET
- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused
on the development of therapeutics that slow the degenerative processes associated with
aging and improve functional outcomes for patients suffering from age-related diseases,
including severe respiratory failure in patients suffering from COVID-19, today announces that
the first French patient has been dosed at La Pitié-Salpêtrière University Hospital, Paris, in
COVA. The COVA study is a Phase 2/3 clinical trial with Sarconeos (BIO101) for the treatment
of patients with COVID-19-related respiratory failure. Dr. Capucine Morelot-Panzini, Professor
of Pulmonology at the Pitié-Salpêtrière University Hospital in Paris is the Principal Investigator
of COVA in France.
In addition to the two first centers at the Pitié-Salpêtrière University Hospital in Paris, Biophytis
also received approval from the French National Agency for Medicines and Health Products
Safety (ANSM) this month to open six new centers in France, among which Centre Hospitalier
Rene Dubos and Centre Hospitalier d’Argenteuil in the Paris Region, bringing the total to eight
centers planned to recruit COVID-19 patients in France.
A total of 17 centers are now actively recruiting in Belgium, Brazil, France and the US among a
targeted number of around thirty to be opened for the second part of the COVA study .
The international COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global,
multicentric, double-blind, placebo-controlled, group-sequential and adaptive two-part Phase
2-3 study assessing Sarconeos (BIO101) in patients aged 45 and older, infected with SARS-CoV2.
This pivotal clinical trial is being conducted in two parts, the first of which will assess the
treatment safety and provide an indication of activity of Sarconeos (BIO101) in 50 hospitalized
patients. The study is designed to evaluate the efficacy and the safety of Sarconeos (BIO101) as
a treatment to prevent further deterioration of patients with COVID-19-related respiratory
failure, which could otherwise require admission to the intensive care units and ventilation.
Press release
The first part of the study is a Phase 2 exploratory proof of concept study to provide preliminary
data on the activity, safety and tolerability of Sarconeos (BIO101) in 50 hospitalized patients
with severe respiratory manifestations related to COVID-19.
The second part of the study will investigate the safety and efficacy of Sarconeos (BIO101) on
the respiratory function of 310 COVID-19 patients (including the 50 patients from Part 1 of the
study).
Interim analysis and completion of full trial enrollment is expected in Q1 2021.
Stanislas Veillet, CEO of Biophytis says: “I am very pleased that after all of the efforts by our
teams over the past few months, we can now announce the first patient has been dosed at La
Pitié-Salpêtrière Hospital and start our COVA clinical program in France. We have been working
for many years with the team at La Pitié-Salpêtrière Hospital, which is linked with Sorbonne
University’s medical school, a long-standing partner of Biophytis. The continued surge of COVID19 cases in France, Europe and the Americas and subsequent hospitalizations, re-emphasizes
the emergency of finding innovative treatments against the pandemic (even while a vaccine is
being rolled-out).
We project enrollment of the 50 patients required for the first part of the study to complete in
the coming weeks. Topline results of the COVA trial are expected in Q2 2021.”
***
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics
that slow the degenerative processes associated with aging and improve functional outcomes for
patients suffering from age-related diseases, including severe respiratory failure in patients suffering
from COVID-19.
Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being
developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARAINT). It is also being studied in a clinical two-part Phase 2/3 study (COVA) for the treatment of severe
respiratory manifestations of COVID-19 in Europe, Latin America and the US.
A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne
Muscular Dystrophy (DMD).
The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares
are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more
information visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. While the Company considers its projections to
be based on reasonable assumptions, these forward-looking statements may be called into question by
Press release
a number of hazards and uncertainties, so that actual results may differ materially from those
anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to
affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change
from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Annual
2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website
(www.biophytis.com).
This press release, and the information contained in it, does not constitute an offer to sell or subscribe,
nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The
elements contained in this communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from those anticipated in this
information due to different risk and uncertainty factors. This press release was written in French and
English; If there is a difference between the texts, the French version will prevail.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com
Media contact
Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91

vantodim1970 11 december 2020 10:48

Ondertussen zitten we al aan de derde freeze van de dag :-)

64 Posts, Pagina: « 1 2 3 4 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 874,79 +8,28 +0,96% 18:05


Germany40^	18.147,90	+1,61%
BEL 20	3.890,71	+0,71%
Europe50^	5.012,03	+1,52%
US30^	38.463,97	+0,56%
Nasd100^	17.448,80	+1,39%
US500^	5.066,70	+0,99%
Japan225^	37.853,71	+0,34%
Gold spot	2.326,78	-0,02%
EUR/USD	1,0705	+0,49%
WTI	83,22	+1,43%